<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on the outcome of children with advanced primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) transplanted from an HLA-matched sibling (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>) or an unrelated donor (UD) following a preparative regimen with <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and melphalan </plain></SENT>
<SENT sid="1" pm="."><plain>Ninety-seven patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, n=53), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, n=29) and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:chebi fb="14" ids="53218">MDR</z:chebi>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, n=15) enrolled in the European Working Group of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in Childhood (EWOG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>Median age at HSCT was 11.1 years (range 1.4-19.0) </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-nine children were transplanted from an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>, whereas 58 were given the allograft from a UD (n=57) or alternative family donor (n=1) </plain></SENT>
<SENT sid="4" pm="."><plain>Stem cell source was bone marrow (n=69) or peripheral blood (n=28) </plain></SENT>
<SENT sid="5" pm="."><plain>With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each </plain></SENT>
<SENT sid="6" pm="."><plain>Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of <z:hpo ids='HP_0011009'>acute</z:hpo> or extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> were associated with increased TRM </plain></SENT>
<SENT sid="7" pm="."><plain>The risk of relapse increased with more advanced disease </plain></SENT>
<SENT sid="8" pm="."><plain>This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>